Work

FDM 3D Printing Filaments with pH-Dependent Solubility: Preparation, Characterization and In Vitro Release Kinetics

Year: 2024

Type: article

Abstract: The process of manufacturing drug delivery systems (DDSs) by fused deposition modeling (FDM) with 3D printing requires the availability of a polymeric filament containing the drug of interest. This filament is fused in the printer heating system and used to print polymer/drug volumetric parts. Polymers with pH-dependent solubility are widely known in the literature for their controlled release and drug dissolution-enhancing properties, biocompatibility, and variety of release profiles. Given these characteristics, the study of pH-responsive 3D printing filaments appears as a potential alternative for the development of new 3D printing functional materials for healthcare area applications. In this sense, this work aimed at the preparation and characterization of pH-dependent filaments of the Eudragit E 100 copolymer (E100) containing the model drug Amlodipine (Aml) for potential application in the manufacturing of DDSs by 3D printing. The E100/Aml filaments with two distinct drug concentrations were produced by hot-melt extrusion at 105 °C. The posterior chemical protonation treatment of the filaments for 60 min provided a significant improvement in their flexibility. Microstructural analysis (SEM, XRD, FTIR, and DLS) and thermal studies by DSC proved the feasibility of producing the filaments by hot-melt extrusion without the degradation of their constituent materials. The in vitro dissolution profiles of the E100/Aml samples were evaluated in simulated gastric and intestinal fluids. The facilitated solubility of the polymer in an acidic medium (pH = 1.2) was preserved in the filament form, with rapid and reproducible drug release from the polymer matrix. The saturation of the drug concentration in the medium occurred after 30 min of testing for E100/Aml models. A customized 3D part with geometry and fill control was also printed from E100/Aml filaments as proof of concept.

Source: Processes

DOI: 10.3390/pr12122916